Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study

Abstract

Background Angiosarcomas (AS) have poor prognosis and often metastasize to distant sites. The potential predictors of metastatic angiosarcomas (MAS) have not been extensively investigated. The main objective of this study was to identify survival predictors of MAS. Methods Surveillance, Epidemiology, and End Results (SEER) datasets were used to identify patients with MAS from 2010 to 2016. Risk predictors were determined with the aid of Kaplan-Meier and Cox regression model analyses. Results A total of 284 MAS patients met the study entry criteria. Among these, 121 patients (42.6%) were diagnosed with metastasis in bone, 26 in brain (9.2%), 86 in liver (30.3%) and 171 in lung (60.2%). Overall, 96 patients (33.8%) had two or more metastatic sites. The 1- and 3-year overall survival (OS) rates were 20.8 and 3.8% while 1- and 3-year cancer-specific survival (CSS) rates were 22.0 and 5.2%, respectively. Cox regression analysis revealed chemotherapy, radiation treatment (RT) and tumor size ≤10 cm as independent favorable predictors of OS. In terms of CSS, tumor grade IV, tumor size > 10 cm and absence of chemotherapy were independent adverse predictors. Surgery did not prolong survival outcomes (both OS and CSS) in the current cohort. Conclusion MAS is associated with extremely poor survival. Chemotherapy, RT, and tumor size are independent predictors of OS. Chemotherapy and tumor size are independent prognostic factors of CSS. Chemotherapy is therefore recommended as the preferred treatment option for MAS patients.

Do Older Patients with Stage IB Non-Small-Cell Lung Cancer Obtain Survival Benefit from Surgery? A Propensity Score Matching Study Based on the SEER Database

“…All cancer studies based on the SEER database are retrospective studies [20,21]. Unlike prospective cohort studies, retrospective studies often have biases in data distribution in terms of baseline characteristics due to the lack of a prior study design [22,23].…”

Angiosarcomas of the head and neck: Impact of large data analysis on clinical management

“…Several studies report that the clinical behavior of angiosarcomas can be gauged by analysis of prognostic factors. 29,[31][32][33][34] Typical prognostic factors associated with poor outcome of angiosarcomas include positive margins, satellite lesions, scalp location, visceral subsite, single modality treatment, older age, previous radiation history, and high stage.…”

Bone metastases with “false negative” findings on 18F-FDG PET/CT in patients with angiosarcoma: A case series with literature review

“…[5,6] Reportedly, angiosarcomas can easily metastasize to other parts of the body through the blood or lymphatic stream, [7] especially in metastatic angiosarcomas, wherein 42.6% of patients developed bone metastases. [8] Although fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is regarded as a reliable and indispensable imaging method for evaluating and staging bone metastases of angiosarcoma, [9][10][11][12][13][14] here we report 2 cases of angiosarcoma with bone metastases that presented with "false negative" findings on 18 F-FDG PET/ CT. To the best of our knowledge, there has been only 1 report…”

“…[ 5 , 6 ] Reportedly, angiosarcomas can easily metastasize to other parts of the body through the blood or lymphatic stream, [ 7 ] especially in metastatic angiosarcomas, wherein 42.6% of patients developed bone metastases. [ 8 ]…”